Tenants In the Louisiana Emerging Technology Center Include:
NuPotential LLC is addressing the high-growth cell therapeutics market by developing new systems for direct cell reprogramming and assessing the state of the cell throughout the reprogramming process.
MaxiFlex, LLC is a spec developer and manufacturer of medical surgical devices, specifically in the field of Urology. Their engineers, coupled with their physician network, bring new and innovative idea for improving medical devices, keeping pace with technology changes. Their commitment is to provide to their customers excellent service and valued products on a timely basis. New surgical products are currently in R&D and are expected to be marketed upon FDA 510K through direct sales and distribution channels.
Esperance Pharmaceuticals is developing a unique targeted anticancer drug that selectively kills cancer cells on contact. Targeting occurs thhrough specific receptors on the cell’s surface. The potent cytotoxic peptide portions of the drug kills even those cells known to be resistant to other common therapeutics.
Qyntessa Biologics provides clinical manufacturing, (cGMP biologics manufacturing), process development, cell banking, cell line development, testing and fill/finish for researchers and biopharmaceutical companies who do not have the facilities and core competencies for clinical manufacturing.
TransGenRx produces proinsulin by using proprietary vector technology to transfer a gene of interest into male and female poultry. The result is stable and heritable insertion for the expression of protein therapeutics. These pharmaceutical-grade protein drugs can be produced for a fraction of the cost of processes currently used and will increase production efficiency.
BioJENC is an emerging biotech company developing peptide vacines against human immunodeficiency virus (HIV) and other challenging infectious agents.
U.S. Antigens is a product and services provider to the biotechnology and research markets. Products include cells, biomass and antibodies. Services offered are custom expression and monoclonal AB production from research to commercial quantities, empowering scientists beyond discovery.
Ox-B
Ox-B Corp is addressing a growing need in a variety of markets by providing a revolutionary disruptive technology that will replace the current products utilized in combating biological contamination.
Ox-B holds an exclusive, worldwide license for all applications of an innovative biocide technology developed at the LSU Ag Center. Ox-B’s products have a wide variety of applications and have already proven effective in eradicating anthrax spores and mold contamination. It also has proven successful in a number of industrial and medical applications, particularly as an intervention technology in combating the presence of Legionella, a disease causing bacteria present in cooling towers. Ox-B’s cold sterilant is extremely effective at combating the rapidly accelerating problem of nosocomial (hospital acquired) infections.